MANEVeradermics Inc
$113.40
$5.49
(5.19%)
Closed $111.32
$2.08
(1.87%)
After Hours
EarningsAug 13
Mkt Cap$4.42B
Vol951,413.00
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study 302 in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study 302 of VDPHL01 in male patients with mild-to-moderate pattern...
Business Wire
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in women with pattern hair loss.read more...
Benzinga
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday
US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition proposal, other big gains from Aehr Test, Electrovaya, Robo.ai, Falcon's Beyond, Veradermics, Lucid Group, Kopin, MINISO, Mesoblast, Nexstar, Lionsgate, Karman.read more...
Benzinga
Veradermics Oral VDPHL01 Delivers Positive Study 207 Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study 306 Readout
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from its open-label Phase 2 clinical trial (Study 207) evaluating VDPHL01, a...
Business Wire
Veradermics to Hold Conference Call to Discuss Study 207 Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from...
Business Wire
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Veradermics (MANE) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Veradermics to Present at Upcoming June Investor Conferences
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June...
Business Wire
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 302 Study of VDPHL01 at the 2026 World Congress for Hair Research
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 302 Study of VDPHL01 will be presented at the 2026 World Congress...
Business Wire
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
Key PointsSiren initiated a new position by acquiring 1,505,374 shares of Veradermics; the estimated transaction value is $75.94 million based on quarterly average pricing...
Nasdaq News: Markets
<
1
2
...
>
Advertisement|Remove ads.
Latest MANE News
ViewVeradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study 302 in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Business Wire
Why Is MANE Stock Rising Today?
Stocktwits
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
Benzinga
SPY20
41
SG2
1
NFLX20
30Advertisement|Remove ads.